Skip to main content

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties Hepatobiliars (GRC)

IP: Rafael Esteban Mur
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Francisco Rodríguez Frias, Silvia Sauleda Oliveras, Victor Manuel Vargas Blasco, Maria Buti Ferret, Torrens Buscató, Maria Margarita, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Análisis de situación y estrategia de manejo de pacientes con infección crónica por VHB sin criterios de tratamiento según las guías de la Asociación Europea para el estudio del hígado

IP: Maria Buti Ferret
Collaborators: Maria del Mar Riveiro Barciela
Funding agency: GILEAD SCIENCES SLU
Funding: 39591
Reference: GLD13/00137
Duration: 18/09/2013 - 17/09/2014

Prevalencia de las quasispecies mutantes en antígeno de superficie en paceintes con hepatitis crónica B y trasplantados por hepatitis B

IP: Maria Buti Ferret
Collaborators: Rafael Esteban Mur, Andrea Caballero Garralda, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 275715.44
Reference: PI11/01973
Duration: 01/01/2012 - 28/02/2015

Análisis de la cuasispecie viral en la infección por virus de la hepatitis B: evolución natural yu asociada al tratamiento antiviral

IP: Francisco Rodríguez Frias
Collaborators: Maria Buti Ferret, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 90750
Reference: PI09/00899
Duration: 01/01/2010 - 31/12/2012

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Borja González Rodríguez

Borja González Rodríguez

Reconstructive Surgery of the Locomotor System
Read more
Joana Rita Marques Soares

Joana Rita Marques Soares

Predoctoral researcher
Systemic Diseases
Read more
Maria Pilar Redondo Gonzalez

Maria Pilar Redondo Gonzalez

Research assistant
Microbiology
Read more
Silvia Muñoz Caller

Silvia Muñoz Caller

Research technician
Psychiatry, Mental Health and Addictions
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.